Please login to the form below

Not currently logged in
Email:
Password:

Noven

This page shows the latest Noven news and features for those working in and with pharma, biotech and healthcare.

Hisamitsu's Noven unit signs Brisdelle deal with Shionogi

Hisamitsu's Noven unit signs Brisdelle deal with Shionogi

Will co-promote the menopausal hot flushes treatment. Noven is to co-promote its menopausal hot flushes treatment Brisdelle (paroxetine) with Shionogi. ... Noven, a US-based subsidiary of Hisamitsu Pharmaceutical, said the deal will help extend physician

Latest news

  • Pfizer enters ADHD market with Quillivant XR launch Pfizer enters ADHD market with Quillivant XR launch

    Shire's Daytrana (methylphenidate; now divested to Noven), Vyvanse (lisdexamfetamine) and Intuniv (guanfacine), as well as Johnson &Johnson's Concerta (methylphenidate).

  • News in brief, July 13, 2007

    Noven added that it expected the acquisition to provide an annual sales of over USD 500m beginning in 2012. ... Following closing, Phillip Satow, CEO and co-founder of JDS, may join Noven's board of directors.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    30. Immunocore/ Eli Lilly. Co-discovery /co-development, options (cost/profit share). ImmTAC (Immune mobilising mTCR Against Cancer) technology (discovery)    . 25+. Noven Therapeutics/ ANI Pharmaceuticals. Acquisition of NDA †. Lithobid

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics